Zellmer, J.; Yen, H.-Y.; Kaiser, L.; Gildehaus, F.J.; Böning, G.; Steiger, K.; Hacker, M.; Bartenstein, P.; Todica, A.; Haug, A.R.;
et al. Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors. Biomedicines 2022, 10, 3102.
https://doi.org/10.3390/biomedicines10123102
AMA Style
Zellmer J, Yen H-Y, Kaiser L, Gildehaus FJ, Böning G, Steiger K, Hacker M, Bartenstein P, Todica A, Haug AR,
et al. Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors. Biomedicines. 2022; 10(12):3102.
https://doi.org/10.3390/biomedicines10123102
Chicago/Turabian Style
Zellmer, Johannes, Hsi-Yu Yen, Lena Kaiser, Franz Josef Gildehaus, Guido Böning, Katja Steiger, Marcus Hacker, Peter Bartenstein, Andrei Todica, Alexander R. Haug,
and et al. 2022. "Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors" Biomedicines 10, no. 12: 3102.
https://doi.org/10.3390/biomedicines10123102
APA Style
Zellmer, J., Yen, H.-Y., Kaiser, L., Gildehaus, F. J., Böning, G., Steiger, K., Hacker, M., Bartenstein, P., Todica, A., Haug, A. R., & Ilhan, H.
(2022). Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors. Biomedicines, 10(12), 3102.
https://doi.org/10.3390/biomedicines10123102
